KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EBT (2016 - 2025)

Historic EBT for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Vertex Pharmaceuticals' EBT rose 610.24% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 161367.49%. This contributed to the annual value of $248.5 million for FY2024, which is 9432.62% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its EBT stood at $1.3 billion for Q3 2025, which was up 610.24% from $1.3 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' EBT ranged from a high of $1.3 billion in Q3 2025 and a low of -$3.4 billion during Q2 2024
  • For the 5-year period, Vertex Pharmaceuticals' EBT averaged around $784.4 million, with its median value being $1.1 billion (2021).
  • In the last 5 years, Vertex Pharmaceuticals' EBT surged by 241764.71% in 2022 and then plummeted by 39196.73% in 2024.
  • Vertex Pharmaceuticals' EBT (Quarter) stood at $870.9 million in 2021, then increased by 23.64% to $1.1 billion in 2022, then rose by 6.58% to $1.1 billion in 2023, then dropped by 0.97% to $1.1 billion in 2024, then rose by 14.28% to $1.3 billion in 2025.
  • Its EBT was $1.3 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $730.4 million in Q1 2025.